Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jan;114(2):262–268. doi: 10.1111/j.1476-5381.1995.tb13221.x

Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A.

D E Hu 1, T P Fan 1
PMCID: PMC1510224  PMID: 7533611

Abstract

1. Vascular endothelial growth factor (VEGF) is a heparin-binding angiogenic factor which specifically acts on endothelial cells via distinct membrane-spanning tyrosine kinase receptors. Here we used the rat sponge implant model to test the hypothesis that the angiogenic activity of VEGF can be suppressed by protein tyrosine kinase (PTK) inhibitors. 2. Neovascular responses in subcutaneous sponge implants were determined by measurements of relative sponge blood flow by use of a 133Xe clearance technique, and confirmed by histological studies and morphometric analysis. 3. Daily local administration of 250 ng VEGF165 accelerated the rate of 133Xe clearance from the sponges and induced an intense neovascularisation. This VEGF165-induced angiogenesis was inhibited by daily co-administration of the selective PTK inhibitor, lavendustin A (10 micrograms), but not its negative control, lavendustin B (10 micrograms). Blood flow measurements and morphometric analysis of 8-day-old sponges showed that lavendustin A reduced the 133Xe clearance of VEGF165-treated sponges from 32.9 +/- 1.5% to 20.9 +/- 1.6% and the total fibrovascular growth area from 62.4 +/- 6.1% to 21.6 +/- 6.8% (n = 12, P < 0.05). 4. Co-injection of suramin (3 mg), an inhibitor of heparin-binding growth factors, also suppressed the VEGF165-elicited neovascular response. In contrast, neither lavendustin A nor suramin produced any effect on the basal sponge-induced angiogenesis. 5. When given alone, low doses of VEGF165 (25 ng) or basic fibroblast growth factor (bFGF; 10 ng) did not modify the basal sponge-induced neovascularisation.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
262

Images in this article

264Figure 2
on p.264
265Figure 2
on p.265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrade S. P., Fan T. P., Lewis G. P. Quantitative in-vivo studies on angiogenesis in a rat sponge model. Br J Exp Pathol. 1987 Dec;68(6):755–766. [PMC free article] [PubMed] [Google Scholar]
  2. Braddock P. S., Hu D. E., Fan T. P., Stratford I. J., Harris A. L., Bicknell R. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer. 1994 May;69(5):890–898. doi: 10.1038/bjc.1994.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coffey R. J., Jr, Leof E. B., Shipley G. D., Moses H. L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol. 1987 Jul;132(1):143–148. doi: 10.1002/jcp.1041320120. [DOI] [PubMed] [Google Scholar]
  4. Connolly D. T. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem. 1991 Nov;47(3):219–223. doi: 10.1002/jcb.240470306. [DOI] [PubMed] [Google Scholar]
  5. Cuevas P., Carceller F., Ortega S., Zazo M., Nieto I., Giménez-Gallego G. Hypotensive activity of fibroblast growth factor. Science. 1991 Nov 22;254(5035):1208–1210. doi: 10.1126/science.1957172. [DOI] [PubMed] [Google Scholar]
  6. Fan T. P. Angiosuppressive therapy for cancer. Trends Pharmacol Sci. 1994 Feb;15(2):33–36. doi: 10.1016/0165-6147(94)90103-1. [DOI] [PubMed] [Google Scholar]
  7. Fan T. P., Hu D. E., Guard S., Gresham G. A., Watling K. J. Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol. 1993 Sep;110(1):43–49. doi: 10.1111/j.1476-5381.1993.tb13769.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ferrara N., Houck K., Jakeman L., Leung D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992 Feb;13(1):18–32. doi: 10.1210/edrv-13-1-18. [DOI] [PubMed] [Google Scholar]
  9. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972 Mar;175(3):409–416. doi: 10.1097/00000658-197203000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  11. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 1992 Jun 5;267(16):10931–10934. [PubMed] [Google Scholar]
  12. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2690–2694. doi: 10.1073/pnas.90.7.2690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993 Nov;69(5):508–517. [PubMed] [Google Scholar]
  14. Hu D. E., Fan T. P. [Leu8]des-Arg9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br J Pharmacol. 1993 May;109(1):14–17. doi: 10.1111/j.1476-5381.1993.tb13525.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hu D. E., Hori Y., Presta M., Gresham G. A., Fan T. P. Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation. 1994 Feb;18(1):45–58. doi: 10.1007/BF01534597. [DOI] [PubMed] [Google Scholar]
  16. Kawakami T., Inagaki N., Takei M., Fukamachi H., Coggeshall K. M., Ishizaka K., Ishizaka T. Tyrosine phosphorylation is required for mast cell activation by Fc epsilon RI cross-linking. J Immunol. 1992 Jun 1;148(11):3513–3519. [PubMed] [Google Scholar]
  17. Kendall R. L., Thomas K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10705–10709. doi: 10.1073/pnas.90.22.10705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  19. Kopp R., Pfeiffer A. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res. 1990 Oct 15;50(20):6490–6496. [PubMed] [Google Scholar]
  20. Kowalski J., Kwan H. H., Prionas S. D., Allison A. C., Fajardo L. F. Characterization and applications of the disc angiogenesis system. Exp Mol Pathol. 1992 Feb;56(1):1–19. doi: 10.1016/0014-4800(92)90019-8. [DOI] [PubMed] [Google Scholar]
  21. La Rocca R. V., Stein C. A., Myers C. E. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells. 1990 Apr;2(4):106–115. [PubMed] [Google Scholar]
  22. Lei Y. H., Barnes P. J., Rogers D. F. Regulation of NANC neural bronchoconstriction in vivo in the guinea-pig: involvement of nitric oxide, vasoactive intestinal peptide and soluble guanylyl cyclase. Br J Pharmacol. 1993 Jan;108(1):228–235. doi: 10.1111/j.1476-5381.1993.tb13467.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mayhew T. M., Sharma A. K. Sampling schemes for estimating nerve fibre size. I. Methods for nerve trunks of mixed fascicularity. J Anat. 1984 Aug;139(Pt 1):45–58. [PMC free article] [PubMed] [Google Scholar]
  24. Millauer B., Wizigmann-Voos S., Schnürch H., Martinez R., Møller N. P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993 Mar 26;72(6):835–846. doi: 10.1016/0092-8674(93)90573-9. [DOI] [PubMed] [Google Scholar]
  25. O'Dell T. J., Kandel E. R., Grant S. G. Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Nature. 1991 Oct 10;353(6344):558–560. doi: 10.1038/353558a0. [DOI] [PubMed] [Google Scholar]
  26. Oikawa T., Hirotani K., Shimamura M., Ashino-Fuse H., Iwaguchi T. Powerful antiangiogenic activity of herbimycin A (named angiostatic antibiotic). J Antibiot (Tokyo) 1989 Jul;42(7):1202–1204. doi: 10.7164/antibiotics.42.1202. [DOI] [PubMed] [Google Scholar]
  27. Olander J. V., Connolly D. T., DeLarco J. E. Specific binding of vascular permeability factor to endothelial cells. Biochem Biophys Res Commun. 1991 Feb 28;175(1):68–76. doi: 10.1016/s0006-291x(05)81201-x. [DOI] [PubMed] [Google Scholar]
  28. Onoda T., Iinuma H., Sasaki Y., Hamada M., Isshiki K., Naganawa H., Takeuchi T., Tatsuta K., Umezawa K. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Nat Prod. 1989 Nov-Dec;52(6):1252–1257. doi: 10.1021/np50066a009. [DOI] [PubMed] [Google Scholar]
  29. Onoda T., Isshiki K., Takeuchi T., Tatsuta K., Umezawa K. Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin A methyl ester in cultured A431 cells. Drugs Exp Clin Res. 1990;16(6):249–253. [PubMed] [Google Scholar]
  30. Pepper M. S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992 Dec 15;189(2):824–831. doi: 10.1016/0006-291x(92)92277-5. [DOI] [PubMed] [Google Scholar]
  31. Plate K. H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993 Dec 1;53(23):5822–5827. [PubMed] [Google Scholar]
  32. Plate K. H., Breier G., Weich H. A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992 Oct 29;359(6398):845–848. doi: 10.1038/359845a0. [DOI] [PubMed] [Google Scholar]
  33. Reilly T. M., Taylor D. S., Herblin W. F., Thoolen M. J., Chiu A. T., Watson D. W., Timmermans P. B. Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo. Biochem Biophys Res Commun. 1989 Oct 31;164(2):736–743. doi: 10.1016/0006-291x(89)91521-0. [DOI] [PubMed] [Google Scholar]
  34. Senger D. R., Van de Water L., Brown L. F., Nagy J. A., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Dvorak A. M., Dvorak H. F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993 Sep;12(3-4):303–324. doi: 10.1007/BF00665960. [DOI] [PubMed] [Google Scholar]
  35. Terman B. I., Dougher-Vermazen M., Carrion M. E., Dimitrov D., Armellino D. C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579–1586. doi: 10.1016/0006-291x(92)90483-2. [DOI] [PubMed] [Google Scholar]
  36. White C. W., Sondheimer H. M., Crouch E. C., Wilson H., Fan L. L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989 May 4;320(18):1197–1200. doi: 10.1056/NEJM198905043201807. [DOI] [PubMed] [Google Scholar]
  37. de Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992 Feb 21;255(5047):989–991. doi: 10.1126/science.1312256. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES